E. Jason Abel, MD, FACS close

E. Jason Abel, MD, FACS Print Friendly Page

Faculty, University of Wisconsin School of Medicine and Public Health

Dr. Abel is board certified by the American Board of Urology and specializes in the surgical treatment of urologic malignancies. He has advanced training to surgically manage all types of genitourinary cancers, including prostate cancer, bladder cancer, kidney cancer, testis cancer and penile cancer.


Dr. Abel performs open and laparoscopic surgery, including surgery using the daVinci robot. His philosophy is to provide maximal quality of life to patients by using minimally invasive approaches to cancer therapy whenever appropriate. He has a special interest in the treatment of localized and locally advanced kidney cancer.



Bladder Cancer


Genitourinary Cancer (Bladder, Kidney, Prostate, Testicular)

Kidney Cancer


Prostate Brachytherapy

Prostate Cancer


Robotic Cystectomy

Robotic Partial Nephrectomy

Robotic Prostatectomy

Testicular Cancer




University Hospital
(608) 263-4757 | (800) 323-8942 | Map

Hospital Affiliation(s)

University Hospital
UnityPoint Health - Meriter
Veterans Hospital - Wm. S. Middleton Memorial

UW School of Medicine and Public Health

Department of Urology

Professional Certifications and Education

Board Certification Urology

Urologic Oncology, M.D. Anderson Cancer Center, Houston, TX

Residency University of Utah Hospital, Salt Lake City, UT
Internship University of Utah Hospital, Salt Lake City, UT
Medical School University of Texas Medical School, Houston, TX

Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.

Dr. Abel conducts clinical, translational and basic research in urologic oncology. He currently is involved in several projects focusing on the development and metastasis of kidney cancer.

PubMed Articles
Etheridge T Liou JI Downs TM Abel EJ Jarrard DF Richards KA The Impact of Agent Orange Exposure on Prostate Cancer Outcomes. J Urol . 2018 Oct 12;
[PubMed ID: 30321553]
Peyton CC Abel EJ Chipollini J Boulware DC Azizi M Karam JA Margulis V Master VA Matin SF Raman JD Sexton WJ Wood CG Spiess PE The Value of Neutrophil to Lymphocyte Ratio in Patients Undergoing Cytoreductive Nephrectomy with Thrombectomy. Eur Urol Focus . 2018 Sep 8;
[PubMed ID: 30206003]
Maciolek KA Abel EJ Best SL Emamekhoo H Averill SL Ziemlewicz TJ Lubner MG Hinshaw JL Lee FT Jr Wells SA Percutaneous microwave ablation for local control of metastatic renal cell carcinoma. Abdom Radiol (NY) . 2018 Sep;43(9):2446-2454
[PubMed ID: 29464274]
Posielski NM Abel EJ Editorial Comment. J Urol . 2018 Sep;200(3):526-527
[PubMed ID: 29928856]
Maciolek KA Best SL Lopez V Posielski N Knoedler M Bushman WA Jarrard DF Downs TM Abel EJ Richards KA Effectiveness of a transrectal prostate needle biopsy protocol with risk-tailored antimicrobials in a veterans cohort. Urol Oncol . 2018 Aug;36(8):363.e13-363.e20
[PubMed ID: 29887242]
Richards KA Liou JI Cryns VL Downs TM Abel EJ Jarrard DF Metformin Use is Associated with Improved Survival for Patients with Advanced Prostate Cancer on Androgen Deprivation Therapy. J Urol . 2018 Jun 22;
[PubMed ID: 29940252]
Etheridge T Liou J Downs TM Abel EJ Richards KA Jarrard DF The impact of celecoxib on outcomes in advanced prostate cancer patients undergoing androgen deprivation therapy. Am J Clin Exp Urol . 2018;6(3):123-132
[PubMed ID: 30038944]
Scrima AT Lubner MG Abel EJ Havighurst TC Shapiro DD Huang W Pickhardt PJ Texture analysis of small renal cell carcinomas at MDCT for predicting relevant histologic and protein biomarkers. Abdom Radiol (NY) . 2018 May 26;
[PubMed ID: 29804215]
Hutchinson R Rew C Chen G Woldu S Krabbe LM Meissner M Sheth K Singla N Shakir N Master VA Karam JA Matin SF Borregales LD Wood C Masterson T Thompson RH Boorjian SA Leibovich BC Abel EJ Bagrodia A Margulis V The Adverse Survival Implications of Bland Thrombus in Renal Cell Carcinoma With Venous Tumor Thrombus. Urology . 2018 May;115:119-124
[PubMed ID: 29499258]
Chipollini J Abel EJ Peyton CC Boulware DC Karam JA Margulis V Master VA Zargar-Shoshtari K Matin SF Sexton WJ Raman JD Wood CG Spiess PE Pathologic Predictors of Survival During Lymph Node Dissection for Metastatic Renal-Cell Carcinoma: Results From a Multicenter Collaboration. Clin Genitourin Cancer . 2018 Apr;16(2):e443-e450
[PubMed ID: 29113770]
Miller BL Abel EJ Editorial Comment. J Urol . 2018 Mar;199(3):639
[PubMed ID: 29227803]
Richards KA Ruiz VL Murphy DR Downs TM Abel EJ Jarrard DF Singh H Diagnostic evaluation of patients presenting with hematuria: An electronic health record-based study. Urol Oncol . 2018 Mar;36(3):88.e19-88.e25
[PubMed ID: 29169843]
Miller BL Mankowski Gettle L Van Roo JR Ziemlewicz TJ Best SL Wells SA Lubner MG Hinshaw JL Lee FT Jr Nakada SY Huang W Abel EJ Comparative Analysis of Surgery, Thermal Ablation, and Active Surveillance for Renal Oncocytic Neoplasms. Urology . 2018 Feb;112:92-97
[PubMed ID: 29030073]
Maciolek KA Jarrard DF Abel EJ Best SL Systematic Assessment Reveals Lack of Understandability for Prostate Biopsy Online Patient Education Materials. Urology . 2017 Nov;109:101-106
[PubMed ID: 28780302]
Abel EJ Masterson TA Karam JA Master VA Margulis V Hutchinson R Lorentz CA Bloom E Bauman TM Wood CG Blute ML Jr Predictive Nomogram for Recurrence following Surgery for Nonmetastatic Renal Cell Cancer with Tumor Thrombus. J Urol . 2017 Oct;198(4):810-816
[PubMed ID: 28411071]
Damodaran S Abel EJ Editorial Comment. Urology . 2017 Oct;108:121
[PubMed ID: 28807653]
Blute ML Jr Kucherov V Rushmer TJ Damodaran S Shi F Abel EJ Jarrard DF Richards KA Messing EM Downs TM Reduced estimated glomerular filtration rate (eGFR &lt;60 mL/min/1.73 m<sup>2</sup> ) at first transurethral resection of bladder tumour is a significant predictor of subsequent recurrence and progression. BJU Int . 2017 Sep;120(3):387-393
[PubMed ID: 28464520]
Shapiro DD Abel EJ Editorial Comment. J Urol . 2017 Sep;198(3):537
[PubMed ID: 28641080]
Best SL Abel EJ Editorial Comment. J Urol . 2017 Aug;198(2):295
[PubMed ID: 28527306]
Abel EJ Spiess PE Margulis V Master VA Mann M Zargar-Shoshtari K Borregales LD Sexton WJ Patil D Matin SF Wood CG Karam JA Cytoreductive Nephrectomy for Renal Cell Carcinoma with Venous Tumor Thrombus. J Urol . 2017 Aug;198(2):281-288
[PubMed ID: 28268170]